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Introduction
Systemic sclerosis (SSc) represents a complex disorder of
obscure etiology which affects the skin as well as various
organs. Cardiac manifestations of SSc may result in peri-
cardial disease, valvular disease, conduction system
abnormalities, and arrhythmias; however, myocardial
fibrosis is the hallmark with major impact on treatment
and patients' prognosis.
Purpose
Thus, our study aimed to assess the potential of contrast
enhanced cardiac MRI for early detection of cardiac
involvement in patients with systemic sclerosis.
Methods
Our study included 35 patients (31 female, 4 male; mean
age, 54 ± 14 years) with known systemic sclerosis and an
age, sex and cardiovascular risk factors matched control
group. Patients with known coronary artery disease
(CAD) or a history of myocardial infarction were excluded
from the study. All examinations were performed on a 1.5
T MR scanner (Magnetom Avanto, Siemens, Germany).
The MRI protocol included Steady-State Free Precession
cine sequences (TrueFISP, TR 3 ms, TE 1.5 ms, FA 60°) in
long and short axis views for the assessment of myocardial
function. Fat-suppressed T2-weighted turbo spin echo
images (TR 2 heart beats, TE 49 ms, FA 180°) in standard
orientations were acquired for the assessment of myocar-
dial edema. Additionally, an inversion-recovery fast low
angle shot sequence (turboFLASH, TR 8 ms, TE 4 ms, TI
180–240 ms, FA 20°) was applied in short and long axis
views 10–15 min after injection of a 0.2 mmol/kg BW of
Gd-DTPA (Magnevist™, Schering AG, Berlin, Germany).
Results
Diagnostic image quality could be achieved in all but one
patient. MRI detected cardiac abnormalities in 50% of our
patients and in 24% of our control group. A reduced ejec-
tion fraction (< 55%) was observed in 7 (21%) SSc
patients, whereas no individual of the control group
showed a reduced ejection fraction (p < 0.05). Pericardial
effusion was observed in 6 (18%) SSc patients and in 1
(3%) control (p > 0.05). Ten (26%) SSc patients and 3
(12%) controls showed valve pathologies (p > 0.05). Nei-
ther a SSc patient nor a control showed myocardial edema
on T2-w images. Late enhancement of a non-ischemic pat-
tern and not corresponding to a coronary territory was
detected in 5 (15%) SSc patients. In all instances, areas of
poorly defined, patchy late enhancement (Figure 1a) and
areas of well defined focal (Figure 1b) were detected in the
mid-myocardial layer. Focal late enhancement was
observed in the mid-myocardial layer of one control (3%,
p > 0.05).
Conclusion
The concept of myocardial late enhancement has been
established for the assessment of myocardial viability. In
chronic myocardial infarction, the accumulation of gado-
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linium-based contrast material reflects irreversible dam-
age and scar formation. However, whereas LE is highly
sensitive in characterizing myocardial scarring, it is not
specific for ischemic damage since contrast agents gener-
ally accumulate in tissues with an increased interstitial
space or areas with cell membrane damage. Thus, LE also
occurs in myocardial areas of inflammation, edema, as
well as fibrosis (Hunold, AJR 2005). Contrast-enhanced
MRI must be considered as the imaging modality of
choice for the detection of myocardial fibrosis in vivo.
Our data show that late enhancement can be detected in
15% of SSc patients with no clinical evidence of myocar-
dial involvement. Therefore, contrast-enhanced MRI
seems to be well suited for screening of myocardial fibro-
sis, monitoring the progression and possibly evaluating
therapeutic effects. However, long-term follow-up studies
are mandatory to investigate the impact of late enhance-
ment on patients' prognosis.
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